View Clinical Trial (Medical Research Study)
A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy - NCT01006122-19114(Clinical Trial 398922)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Philadelphia |
|
State:
|
|
PA |
| Zip Code: |
|
19114 |
| Conditions: |
|
Excessive Daytime Sleepiness - Narcolepsy |
| Purpose: |
|
Histaminergic agents are known to be involved with the sleep/wake cycle. This compound is a
histaminergic agent which therefore may improve alertness and awakeness in patients with
excessive daytime sleepiness (EDS) associated with narcolepsy. Significant improvement in
EDS when treated with this compound compared to placebo in patients with narcolepsy is
hypothesized.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- ISDC diagnosis of narcolepsy
- Excessive Daytime Sleepiness in association with a diagnosis of narcolepsy
- An MWT (Maintenance of Wakefulness Test) average sleep latency of under 15 minutes at
Baseline
Exclusion Criteria:
- No other diagnosed sleep disorders (e.g., sleep apnea)
- Major medical disorders
- Major psychiatric disorders |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
August 16, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|